In December 2024, Roche announced the cessation of further development of SPK-8011, a key gene therapy for hemophilia A. This decision follows Roche's $4.3 billion acquisition of Spark Therapeutics in 2019, aimed at strengthening their gene therapy capabilities, particularly for genetic eye and blood disorders. Despite initial expectations, some of Spark's projects have not progressed as planned, with some being discontinued.
Roche's acquisition of Spark Therapeutics was a strategic move to enhance its market competitiveness in gene therapy. The acquisition included products like Luxturna, a gene therapy for inherited retinal diseases, which continues to expand globally under Roche's network.
In July 2023, Roche also discontinued SPK-8016, another hemophilia A therapy, due to strategic adjustments. SPK-9001 for hemophilia B and SPK-7001 for choroideremia remain under evaluation. Roche's commitment to innovation in gene therapy suggests long-term potential despite current challenges.
